Financial Data and Key Metrics Changes - As of March 31, 2024, the company had approximately $297 million in cash and marketable securities, with an expected cash runway lasting into the first half of 2027 [10] - R&D expenses for Q1 2024 were $12.4 million, an increase attributed to spending for the ALTITUDE-AD trial [11] - G&A expenses were $5.3 million for the quarter, reflecting an increase due to higher headcount, leading to a loss from operations of $17.8 million [11] Business Line Data and Key Metrics Changes - The ALTITUDE-AD Phase II study has commenced, with the first patient dosed, aiming to evaluate the efficacy and safety of sabirnetug in approximately 540 participants [7][8] - The company is also on track to initiate a Phase I study for a subcutaneous formulation of sabirnetug in mid-2024, which is expected to provide additional flexibility for patients [9] Market Data and Key Metrics Changes - The company is encouraged by the early engagement and interest from trial sites for the ALTITUDE study, which may be positively influenced by the Phase I INTERCEPT results [7][27] Company Strategy and Development Direction - The company aims to establish sabirnetug as a best-in-class treatment for early Alzheimer's patients, focusing on advancing clinical development efficiently [9] - A collaboration agreement with Lonza for manufacturing sabirnetug has been established, leveraging Lonza's expertise for clinical development and commercialization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the ALTITUDE study's early progress and the potential for sabirnetug to provide significant value to patients and shareholders [9][27] - The company is closely monitoring the implications of competing products like lecanemab and donanemab on enrollment expectations for the ALTITUDE study [26][27] Other Important Information - The company is committed to delivering updates throughout the year as it advances the sabirnetug program [11] Q&A Session Summary Question: Is R&D about stable now, or are we expecting it to go up significantly? - R&D is expected to trend up for the next couple of quarters before flattening out and then decreasing [12][13] Question: Do you have a sense of what you're looking for in the subcutaneous formulation? - The focus is on getting the healthy volunteer study up and evaluating pharmacokinetics, with considerable optionality for future steps [14][15] Question: Can you ultimately get to a plaque-busting dose with the subcutaneous formulation? - The goal remains consistent with the INTERCEPT study, focusing on oligomer target engagement and some plaque reduction [18][19] Question: What are the implications of the upcoming donanemab AdComm? - The AdComm will focus on treatment duration and stratification concerns, which may have implications for market development [20] Question: Can the subcutaneous formulation be used within ALTITUDE if the healthy volunteer study goes well? - While theoretically possible, it would be logistically challenging to insert the subcutaneous formulation into the already designed ALTITUDE study [28][29]

Exhibit 99.1 Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid- 2024 • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activi ...

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, ...

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET). The live webcast may be accessed under the Investors tab on www.acum ...

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) fo ...

Core Viewpoint - Acumen Pharmaceuticals has partnered with Lonza to manufacture its monoclonal antibody candidate, sabirnetug (ACU193), aimed at treating Alzheimer's disease by targeting toxic soluble amyloid beta oligomers [1][2]. Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease, specifically targeting toxic soluble amyloid beta oligomers (AβOs) [4]. - The company is headquartered in Charlottesville, Virginia, with additional offices in Indianapolis, Indiana, and Newton, Massachusetts [4]. - Acumen's scientific founders have pioneered research on AβOs, which are believed to be early triggers of Alzheimer's disease pathology [4]. Product Development - Sabirnetug (ACU193) is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in a Phase 1 clinical study [2]. - The drug aims to prevent toxic AβOs from binding to dendritic spines, thereby preserving neuronal function and addressing an underlying cause of Alzheimer's disease [2]. - Acumen plans to initiate a Phase 2 clinical trial for sabirnetug in the first half of 2024 [1]. Manufacturing Collaboration - Under the agreement, Lonza will manufacture sabirnetug at its next-generation facility in Portsmouth, New Hampshire, utilizing 2,000L single-use bioreactors [2]. - Lonza's expertise in regulatory compliance and antibody manufacturing will support Acumen in advancing its clinical development [2][3]. - The collaboration is seen as a critical step for Acumen to ensure broader access to next-generation Alzheimer's therapies [3]. Lonza Overview - Lonza is a leading global healthcare manufacturing organization with a workforce of around 18,000 employees [5]. - The company generated sales of CHF 6.7 billion and a CORE EBITDA of CHF 2.0 billion in the full year 2023 [5]. - Lonza operates across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients, providing comprehensive support to pharmaceutical and biotech companies [5].

One stock that might be an intriguing choice for investors right now is Acumen Pharmaceuticals, Inc. (ABOS) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ...

Corporate Presentation March 2024 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expr ...

Financial Performance - The net loss for the year ended December 31, 2023, was $52,371 thousand, compared to a net loss of $42,856 thousand in 2022, indicating a 22.5% increase in losses [500]. - The comprehensive loss for 2023 was $51,308 thousand, compared to $43,376 thousand in 2022, reflecting an 18.4% increase [500]. - The company reported a net loss of $52.4 million for the year ended December 31, 2023, compared to a net loss of $42.9 million for the previous year, reflecting an increase in losses of approximately 22% [506]. - The company incurred $6.1 million in stock-based compensation expense in 2023, compared to $3.1 million in 2022, reflecting a 99% increase year-over-year [506]. - The company reported net cash used in operating activities of $43.1 million for 2023, compared to $35.2 million for 2022, indicating a 22% increase in cash outflows [506]. Assets and Liabilities - As of December 31, 2023, total assets were $310,125 thousand, an increase from $196,587 thousand in 2022, representing a 57.7% growth [498]. - The company’s balance sheet shows a cash position of $66,886 thousand as of December 31, 2023, down from $130,101 thousand in 2022, a decrease of 48.5% [498]. - As of December 31, 2023, the company had an accumulated deficit of $222.8 million, up from $170.4 million at the end of 2022, indicating a significant increase in accumulated losses [510]. - The company had working capital of $233.6 million as of December 31, 2023, compared to $172.5 million at the end of 2022, showing an increase of approximately 35% [510]. Revenue and Income - The company reported interest income of $10,791 thousand in 2023, significantly higher than $2,392 thousand in 2022, representing a 350.5% increase [500]. Research and Development - Research and development expenses increased to $42,318 thousand in 2023 from $32,361 thousand in 2022, marking a 30.9% rise [500]. - Research and development expenses primarily consist of costs related to consultants, materials, and clinical trials, which are expensed as incurred [539]. - The company expects to initiate a Phase 2 clinical trial of its drug candidate sabirnetug in the first half of 2024, following successful Phase 1 results reported in July 2023 [513]. - The Phase 1 clinical trial, named INTERCEPT-AD, enrolled 65 patients with early Alzheimer's disease, with 62 participants receiving at least one dose of the study drug [512]. - The Company recorded R&D expenses related to the Halozyme License Agreement, including a seven-figure upfront payment, as the Halozyme Product is still in the development stage [614]. Stock and Equity - The weighted-average shares outstanding increased to 48,609,383 in 2023 from 40,601,936 in 2022, a growth of 19.8% [500]. - The Company has a total of 310 million authorized shares, with 300 million designated as Common Stock [584]. - The maximum number of shares that may be issued under the 2021 Equity Incentive Plan is 12 million, with 11,773,198 shares authorized for issuance and 3,674,730 shares remaining available as of December 31, 2023 [591]. - The intrinsic value of stock options exercised in 2023 was approximately $0.5 million, while the total unrecognized compensation costs related to unvested stock options was about $12.3 million [600]. - The Company granted 328,500 Restricted Stock Units (RSUs) in January 2023, with a weighted average fair value of $6.11 per share, and total unrecognized compensation costs related to unvested RSUs was approximately $1.4 million [602]. Financing and Capital Structure - The company raised $121.9 million in a public offering on July 21, 2023, issuing 16,774,193 shares at a price of $7.75 per share [509]. - The Company entered into a Term Loan Agreement for a principal amount of $50 million, borrowing $30 million in the first tranche, with an interest rate of 9.65% or the prime rate plus 1.15% [568]. - The effective interest rate for the Term Loan was reported at 14.3% for the year ended December 31, 2023 [573]. - The Company plans to finance its operations through a combination of equity offerings, debt financings, and collaborations, indicating ongoing reliance on external funding sources [511]. Tax and Deferred Tax Assets - The Company has not recorded any tax provision or benefit for federal income taxes for the years ended December 31, 2023 and 2022, with a statutory federal income tax rate of 21% [605]. - The total deferred tax assets as of December 31, 2023 amounted to $34.098 million, with a valuation allowance of $33.661 million recorded [608]. - The Company has not adjusted any of its deferred tax assets, including NOLs or R&D credits, pending a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2023 [610]. Marketable Securities - The company's total available-for-sale securities amounted to $239,189,000 as of December 31, 2023, with gross unrealized losses of $212,000 [554]. - The fair value of the company's total financial assets was $305,396,000 as of December 31, 2023, with significant contributions from corporate debt and U.S. treasury securities [559]. - The company's marketable securities portfolio consists entirely of available-for-sale debt securities, with short-term securities maturing within one year and long-term securities within two years [557]. - The fair value of embedded derivatives in the Term Loan increased from $1.2 million at issuance to $2.56 million by December 31, 2023, reflecting a change of $1.36 million [563]. Other Financial Information - The Company recorded no liabilities related to uncertain tax positions as of December 31, 2023 and 2022, indicating no significant tax-related risks [545]. - The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero, reflecting uncertainty in realizing these assets [544]. - The Company did not require an allowance for credit losses for available-for-sale securities as of December 31, 2023, as the aggregate amount of credit loss was immaterial [525]. - The Company maintains deposits in financial institutions in excess of government insured limits but believes it is not exposed to significant credit risk [526]. - The Company recorded a non-cash expense of $0.7 million related to the right-of-use assets for a computer equipment lease used in R&D [578].

Corporate Presentation March 2024 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “would,” “seeks,” “aims,” “plans,” “potential,” “will” and similar ex ...